The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsui, S.
Right arrow Articles by Berzofsky, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsui, S.
Right arrow Articles by Berzofsky, J. A.
The Journal of Immunology, 1999, 163: 184-193.
Copyright © 1999 by The American Association of Immunologists

A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL

So Matsui*, Jeffrey D. Ahlers*, Alex O. Vortmeyer{dagger}, Masaki Terabe*, Taku Tsukui*, David P. Carbone{ddagger}, Lance A. Liotta{dagger} and Jay A. Berzofsky1,*

* Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, and {dagger} Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and {ddagger} Department of Medicine, Vanderbilt Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232

Understanding immune mechanisms influencing cancer regression, recurrence, and metastasis may be critical to developing effective immunotherapy. Using a tumor expressing HIV gp160 as a model viral tumor Ag, we found a growth-regression-recurrence pattern, and used this to investigate mechanisms of immunosurveillance. Regression was dependent on CD8 T cells, and recurrent tumors were resistant to CTL, had substantially reduced expression of epitope mRNA, but retained the gp160 gene, MHC, and processing apparatus. Increasing CTL numbers by advance priming with vaccinia virus expressing gp160 prevented only the initial tumor growth but not the later appearance of escape variants. Unexpectedly, CD4 cell depletion protected mice from tumor recurrence, whereas IL-4 knockout mice, deficient in Th2 cells, did not show this protection, and IFN-{gamma} knockout mice were more susceptible. Purified CD8 T cells from CD4-depleted mice following tumor regression had more IFN-{gamma} mRNA and lysed tumor cells without stimulation ex vivo, in contrast to CD4-intact mice. Thus, the quality as well as quantity of CD8+ CTL determines the completeness of immunosurveillance and is controlled by CD4 T cells but not solely Th2 cytokines. This model of immunosurveillance may indicate ways to enhance the efficacy of surveillance and improve immunotherapy.




This article has been cited by other articles:


Home page
 JCOHome page
C. L. Slingluff Jr, G. R. Petroni, W. Olson, A. Czarkowski, W. W. Grosh, M. Smolkin, K. A. Chianese-Bullock, P. Y. Neese, D. H. Deacon, C. Nail, et al.
Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens
J. Clin. Oncol., October 20, 2008; 26(30): 4973 - 4980.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al.
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Fichtner-Feigl, M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H.-J. Schlitt, J. A. Berzofsky, and W. Strober
Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-{alpha}2
Cancer Res., May 1, 2008; 68(9): 3467 - 3475.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Ambrosino, M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky
Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis
J. Immunol., October 15, 2007; 179(8): 5126 - 5136.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. Dvorkin, X. Song, S. Argov, R. M. White, M. Zoller, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte
Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1{alpha}
J. Leukoc. Biol., July 1, 2006; 80(1): 96 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Terabe, C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C. L. Mackall, L. J. Helman, and J. A. Berzofsky
CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor-{beta}.
Cancer Res., April 1, 2006; 66(7): 3869 - 3875.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Terabe, J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky
A nonclassical non-V{alpha}14J{alpha}18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
J. Exp. Med., December 19, 2005; 202(12): 1627 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Preville, D. Ladant, B. Timmerman, and C. Leclerc
Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein
Cancer Res., January 15, 2005; 65(2): 641 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Rayman, A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al.
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses
Clin. Cancer Res., September 15, 2004; 10(18): 6360S - 6366S.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. C. Bartholomae, F. H. Rininsland, J. C. Eisenberg, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann
T Cell Immunity Induced by Live, Necrotic, and Apoptotic Tumor Cells
J. Immunol., July 15, 2004; 173(2): 1012 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Conticello, F. Pedini, A. Zeuner, M. Patti, M. Zerilli, G. Stassi, A. Messina, C. Peschle, and R. De Maria
IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins
J. Immunol., May 1, 2004; 172(9): 5467 - 5477.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Terabe, S. Matsui, J.-M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al.
Transforming Growth Factor-{beta} Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte-mediated Tumor Immunosurveillance: Abrogation Prevents Tumor Recurrence
J. Exp. Med., December 1, 2003; 198(11): 1741 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Numasaki, J.-i. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, H. Tahara, and M. T. Lotze
Interleukin-17 promotes angiogenesis and tumor growth
Blood, April 1, 2003; 101(7): 2620 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
B. Maletto, A. Ropolo, V. Moron, and M. C. Pistoresi-Palencia
CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice
J. Leukoc. Biol., September 1, 2002; 72(3): 447 - 454.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Oelmann, H. Herbst, M. Zuhlsdorf, O. Albrecht, A. Nolte, C. Schmitmann, O. Manzke, V. Diehl, H. Stein, and W. E. Berdel
Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells
Blood, January 1, 2002; 99(1): 258 - 267.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. M.-Y. Sze, G. Giesajtis, R. D. Brown, M. Raitakari, J. Gibson, J. Ho, A. G. Baxter, B. Fazekas de St Groth, A. Basten, and D. E. Joshua
Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment
Blood, November 1, 2001; 98(9): 2817 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. K. Polakos, D. Drane, J. Cox, P. Ng, M. J. Selby, D. Chien, D. T. O'Hagan, M. Houghton, and X. Paliard
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine
J. Immunol., March 1, 2001; 166(5): 3589 - 3598.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Derby, M. A. Alexander-Miller, R. Tse, and J. A. Berzofsky
High-Avidity CTL Exploit Two Complementary Mechanisms to Provide Better Protection Against Viral Infection Than Low-Avidity CTL
J. Immunol., February 1, 2001; 166(3): 1690 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Zheng, P. Palese, and A. García-Sastre
Antitumor Properties of Influenza Virus Vectors
Cancer Res., December 1, 2000; 60(24): 6972 - 6976.
[Abstract] [Full Text]

Home page
 Infect. Immun.Home page
G. Dadaglio, Z. Moukrim, R. Lo-Man, V. Sheshko, P. Sebo, and C. Leclerc
Induction of a Polarized Th1 Response by Insertion of Multiple Copies of a Viral T-Cell Epitope into Adenylate Cyclase of Bordetella pertussis
Infect. Immun., July 1, 2000; 68(7): 3867 - 3872.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Prevost-Blondel, E. Roth, F. M. Rosenthal, and H. Pircher
Crucial Role of TNF-{alpha} in CD8 T Cell-Mediated Elimination of 3LL-A9 Lewis Lung Carcinoma Cells In Vivo
J. Immunol., April 1, 2000; 164(7): 3645 - 3651.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.